Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Alterations in the RTK/Ras/PI3K/AKT pathway serve as potential biomarkers for immunotherapy outcome of diffuse gliomas.

Aging - 8 Jun 2021

Han Song, Wang Peng-Fei, Cai Hong-Qing, Wan Jing-Hai, Li Shou-Wei, Lin Ze-Huan, Yu Chun-Jiang, Yan Chang-Xiang

Abstract excerpt

BACKGROUND: Diffuse gliomas are the most common malignant brain tumors, and immune checkpoint inhibitors have limited therapeutic effects against this cancer. Three oncogenic pathways are altered in diffuse gliomas: the RTK/Ras/PI3K/AKT signaling, TP53, and RB pathways. Although these pathways may affect the tumor immune microenvironment, their association with immunotherapy biomarkers remains unclear. METHODS:...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Glioma
Share to Immunotherapy

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Multivariate Analysis

Share to Phosphatidylinositol 3-Kinases

Share to Proto-Oncogene Proteins c-akt

Share to ras Proteins

Share to Receptor Protein-Tyrosine Kinases

Share to Survival Analysis

Source

Open in PubMed Open full text

Identifiers

PMID: 34100771
DOI: 10.18632/aging.203102
PMCID: PMC8221357

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Alterations in the RTK/Ras/PI3K/AKT pathway serve as potential biomarkers for immunotherapy outcome of diffuse gliomas.PMID 34100771Read ↗

Integrative cBioPortal Analysis Revealed Molecular Mechanisms That Regulate EGFR-PI3K-AKT-mTOR Pathway in Diffuse Gliomas of the BrainSemantic proximity Read ↗

Systematic Review of Molecular Targeted Therapies for Adult-Type Diffuse Glioma: An Analysis of Clinical and Laboratory Studies.Semantic proximity Read ↗

PD-1 related transcriptome profile and clinical outcome in diffuse gliomasSemantic proximity Read ↗

Molecular Profiling Reveals Biologically Discrete Subsets and Pathways of Progression in Diffuse Glioma.Semantic proximity Read ↗

Tumor mutational burden is associated with poor outcomes in diffuse glioma.Semantic proximity Read ↗

Comprehensive exploration of tumor mutational burden and immune infiltration in diffuse glioma.Semantic proximity Read ↗

Tumor Mutational Burden is Associated with Poor Outcomes in Diffuse Glioma.Semantic proximity Read ↗

Integrated longitudinal analysis of adult grade 4 diffuse gliomas with long-term relapse interval revealed upregulation of TGF-β signaling in recurrent tumorsSemantic proximity Read ↗

PI3 kinase mutations and mutational load as poor prognostic markers in diffuse glioma patients.Semantic proximity Read ↗

Genomically amplified Akt3 activates DNA repair pathway and promotes glioma progressionSemantic proximity Read ↗

Targeted therapy for malignant glioma patients: lessons learned and the road ahead.Semantic proximity Read ↗

PI3K/AKT/mTOR signaling pathway activity in IDH-mutant diffuse glioma and clinical implications.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.